Investigator, BC Mental Health and Substance Use Services Research Institute
- Investigator, BC Mental Health and Substance Use Services Research Institute
- Investigator, BC Children's Hospital Research Institute
- Clinical Professor, Department of Psychiatry, University of British Columbia
- Adjunct Professor, Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia
Dr. Ric Procyshyn holds the position of clinical research psychopharmacologist at the BC Mental Health and Substance Use Services Research Institute and acts as a consultant for the BC Psychosis Program. Along with his doctor of pharmacy degree, Dr. Procyshyn possesses a Ph.D. in medicinal chemistry. He has authored over 170 articles in peer-reviewed journals and is the principal editor of the Clinical Handbook of Psychotropic Drugs. He is also is the co-developer of the SwitchRx website. Dr. Procyshyn enjoys teaching and has been awarded several teaching awards from the Faculty of Pharmaceutical Sciences at the University of British Columbia.
Antipsychotic polypharmacy and the prevalence, predictors, indicators and clinical outcomes with this relatively common prescribing practice that is not adequately supported by literature or clinical practice guidelines.
Smoking and schizophrenia research on the relationship between tobacco consumption and antipsychotic treatment, self-reported motivations for why persons living with schizophrenia smoke, and predictors of starting to smoke in first-episode patients.
The influence of serum lipids on clozapine’s clinical efficacy, including possible mechanism(s) that underlie previous work showing a positive correlation between serum triglycerides and clinical response to clozapine, and the metabolic effects of antipsychotics, including an investigation of the acute and chronic effects of the atypical antipsychotics on alterations in glucose and insulin parameters.See Dr. Ric Procyshyn's publications on ORCID
Kim DD, Barr A, Lian L, Fredrikson D, Honer W, Thornton A, Procyshyn RM. Efficacy and tolerability of dopamine D2 receptor partial agonists versus D2 receptor antagonists in early psychosis: A systematic review and meta-analysis. Biological Psychiatry 2020;87(9):S281
Kim DD, Barr AM, Lu C, Stewart SE, White RF, Honer WG, Procyshyn RM. Clozapine-associated obsessive-compulsive symptoms and their management: A systematic review and analysis of 107 cases. Psychotherapy and Psychosomatics. 2020. DOI: 10.1159/000505876
Procyshyn RM, Lamoure JW, Katzman MA, Skinner PL, Sherman SE. Need for bioequivalence standards that reflect the clinical importance of the complex pharmacokinetics of paliperidone palmitate long-acting injectable suspension. Journal of Pharmacy and Pharmaceutical Sciences. 2019;22:548-566
Downing L, Kim DD, Procyshyn RM, Tibo P. Management of sexual adverse effects induced by atypical antipsychotic medication. Journal of Psychiatry and Neuroscience. 2019;44:287-288
Kim DD, Barr AM, Fredrikson DH, Honer WG, Procyshyn RM. Association between serum lipids and antipsychotic response in schizophrenia. Current Neuropharmacology 2019; DOI: 10.2174/1570159X17666190228113348
Kim DD, Barr AM, White RF, Honer WG, Procyshyn RM. Clozapine-induced obsessive-compulsive symptoms: mechanisms and treatment. Journal of Psychiatry and Neuroscience 2019;44:71-72
Kim DD, Barr AM, Chung Y, Yuen JWY, Etminan M, Carleton BC, White RF, Honer WG, Procyshyn RM. Antipsychotic-associated symptoms of Tourette syndrome: A systematic review. CNS Drugs 2018. DOI: 10.1007/S40263-018-0559-8
Kim DD, Barr AM, Honer WG, Procyshyn RM. Reversal of dopamine supersensitivity as a mechanism of action of clozapine. Psychotherapy and Psychosomatics 2018; DOI:10.1159/000491700
Kim DD, Barr AM, Thornton AE, Honer WG, Procyshyn RM. Statin add-on for schizophrenia: Is the effect the same for clozapine? [Letter to the Editor] Psychiatry Research 2018;263:289-290.
Kim DD, Barr AM, Honer WG, Procyshyn RM. Exercise-induced hippocampal neurogenesis: 5-HT3 receptor antagonism by antipsychotics as a potential limiting factor. Molecular Psychiatry 2018; doi:10.1038/s41380-018-0022-8
Procyshyn RM (Principal Editor), Bezchlibnyk-Butler K (Co-Editor), Jeffries J (Co-Editor). Clinical Handbook of Psychotropic Drugs, 24th edition (ISBN 9781616765934). Hogrefe Publishing.
Elbe D (Principal Editor), Procyshyn RM (Co-Editor), Black TR (Co-Editor), McGrane, IR (Co-Editor). Clinical Handbook of Psychotropic Drugs for Children and Adolescents, 4th edition (ISBN 9780889375505). Hogrefe Publishing.
The Clinical Handbook of Psychotropic Drugs is a user-friendly practical resource for using psychotropic drugs in any setting. The content stems from publications including randomized controlled trials, scientific data such as pharmacokinetic trials, cohort trials, case series, and case reports. Leading clinical experts provide evidence-based relevant information that is easily accessed and helps with patient care decisions
Developers: Ric M. Procyshyn & Diane McIntosh
SwitchRx provides healthcare professionals with the most current and useful information to guide their clinical practice when adjusting their patient's psychotropic treatment regimens. This resource features suggested tapering and titration schedules, clinical tips, detailed information on drug pharmacokinetics, and other precautions. Clinical practice guidelines and psychiatric rating scales are also available to users.